HRP20120837T1 - Derivati piperidina - Google Patents
Derivati piperidina Download PDFInfo
- Publication number
- HRP20120837T1 HRP20120837T1 HRP20120837AT HRP20120837T HRP20120837T1 HR P20120837 T1 HRP20120837 T1 HR P20120837T1 HR P20120837A T HRP20120837A T HR P20120837AT HR P20120837 T HRP20120837 T HR P20120837T HR P20120837 T1 HRP20120837 T1 HR P20120837T1
- Authority
- HR
- Croatia
- Prior art keywords
- indol
- piperidin
- carbonyl
- alkyl
- methylpropan
- Prior art date
Links
- 150000003053 piperidines Chemical class 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 201000004384 Alopecia Diseases 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 201000009273 Endometriosis Diseases 0.000 claims 3
- 206010020112 Hirsutism Diseases 0.000 claims 3
- 206010020880 Hypertrophy Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 206010039792 Seborrhoea Diseases 0.000 claims 3
- 206010000496 acne Diseases 0.000 claims 3
- 230000001919 adrenal effect Effects 0.000 claims 3
- 231100000360 alopecia Toxicity 0.000 claims 3
- 230000003676 hair loss Effects 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 201000003349 lung leiomyoma Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 3
- 230000002028 premature Effects 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- LHIOQIJQDSAMED-UHFFFAOYSA-N (3,5-dimethyl-1h-indol-2-yl)-[4-(2-hydroxy-2-methylpropyl)piperidin-1-yl]methanone Chemical compound N1C2=CC=C(C)C=C2C(C)=C1C(=O)N1CCC(CC(C)(C)O)CC1 LHIOQIJQDSAMED-UHFFFAOYSA-N 0.000 claims 1
- LVGBDWPXOTWIPE-UHFFFAOYSA-N (4-chloro-1h-indol-2-yl)-[4-(2-hydroxy-2-methylpropyl)piperidin-1-yl]methanone Chemical compound C1CC(CC(C)(O)C)CCN1C(=O)C1=CC2=C(Cl)C=CC=C2N1 LVGBDWPXOTWIPE-UHFFFAOYSA-N 0.000 claims 1
- NDGKIPXQQIZYGN-UHFFFAOYSA-N (4-fluoro-1h-indol-2-yl)-[4-(2-hydroxy-2-methylpropyl)piperidin-1-yl]methanone Chemical compound C1CC(CC(C)(O)C)CCN1C(=O)C1=CC2=C(F)C=CC=C2N1 NDGKIPXQQIZYGN-UHFFFAOYSA-N 0.000 claims 1
- FQYKMNLKINGDRP-UHFFFAOYSA-N (5-bromo-1h-indol-2-yl)-[4-(2-hydroxy-2-methylpropyl)piperidin-1-yl]methanone Chemical compound C1CC(CC(C)(O)C)CCN1C(=O)C1=CC2=CC(Br)=CC=C2N1 FQYKMNLKINGDRP-UHFFFAOYSA-N 0.000 claims 1
- CBQYEEYWASFMNH-UHFFFAOYSA-N (5-chloro-1h-indol-2-yl)-[4-(2-hydroxy-2-methylpropyl)piperidin-1-yl]methanone Chemical compound C1CC(CC(C)(O)C)CCN1C(=O)C1=CC2=CC(Cl)=CC=C2N1 CBQYEEYWASFMNH-UHFFFAOYSA-N 0.000 claims 1
- HPJJYDDEEIACJH-UHFFFAOYSA-N (5-fluoro-1h-indol-2-yl)-[4-(2-hydroxy-2-methylpropyl)piperidin-1-yl]methanone Chemical compound C1CC(CC(C)(O)C)CCN1C(=O)C1=CC2=CC(F)=CC=C2N1 HPJJYDDEEIACJH-UHFFFAOYSA-N 0.000 claims 1
- RRRYIWYIJMGXKU-UHFFFAOYSA-N (5-hydroxy-1h-indol-2-yl)-[4-(2-hydroxy-2-methylpropyl)piperidin-1-yl]methanone Chemical compound C1CC(CC(C)(O)C)CCN1C(=O)C1=CC2=CC(O)=CC=C2N1 RRRYIWYIJMGXKU-UHFFFAOYSA-N 0.000 claims 1
- IZWDDAUSBMQEDB-UHFFFAOYSA-N (5-tert-butyl-1h-indol-2-yl)-[4-(2-hydroxy-2-methylpropyl)piperidin-1-yl]methanone Chemical compound C1CC(CC(C)(O)C)CCN1C(=O)C1=CC2=CC(C(C)(C)C)=CC=C2N1 IZWDDAUSBMQEDB-UHFFFAOYSA-N 0.000 claims 1
- WCOIKBTVFHWVFM-UHFFFAOYSA-N (7-chloro-5-fluoro-1h-indol-2-yl)-[4-(2-hydroxy-2-methylpropyl)piperidin-1-yl]methanone Chemical compound C1CC(CC(C)(O)C)CCN1C(=O)C1=CC2=CC(F)=CC(Cl)=C2N1 WCOIKBTVFHWVFM-UHFFFAOYSA-N 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- IINOFUOFXJJMDX-UHFFFAOYSA-N [4-(2-hydroxy-2-methylpropyl)piperidin-1-yl]-(1h-indol-2-yl)methanone Chemical compound C1CC(CC(C)(O)C)CCN1C(=O)C1=CC2=CC=CC=C2N1 IINOFUOFXJJMDX-UHFFFAOYSA-N 0.000 claims 1
- WTFDPMXUUORQDE-UHFFFAOYSA-N [4-(2-hydroxy-2-methylpropyl)piperidin-1-yl]-(4-methoxy-1h-indol-2-yl)methanone Chemical compound C=1C=2C(OC)=CC=CC=2NC=1C(=O)N1CCC(CC(C)(C)O)CC1 WTFDPMXUUORQDE-UHFFFAOYSA-N 0.000 claims 1
- XGWJZHUZUSSMHK-UHFFFAOYSA-N [4-(2-hydroxy-2-methylpropyl)piperidin-1-yl]-(4-methyl-1h-indol-2-yl)methanone Chemical compound C=1C=2C(C)=CC=CC=2NC=1C(=O)N1CCC(CC(C)(C)O)CC1 XGWJZHUZUSSMHK-UHFFFAOYSA-N 0.000 claims 1
- OXSCPDKUZWPWFR-UHFFFAOYSA-N [4-(2-hydroxy-2-methylpropyl)piperidin-1-yl]-(5-methoxy-1h-indol-2-yl)methanone Chemical compound C=1C2=CC(OC)=CC=C2NC=1C(=O)N1CCC(CC(C)(C)O)CC1 OXSCPDKUZWPWFR-UHFFFAOYSA-N 0.000 claims 1
- QGUMEWLTIYRZFH-UHFFFAOYSA-N [4-(2-hydroxy-2-methylpropyl)piperidin-1-yl]-(5-methyl-1h-indol-2-yl)methanone Chemical compound C=1C2=CC(C)=CC=C2NC=1C(=O)N1CCC(CC(C)(C)O)CC1 QGUMEWLTIYRZFH-UHFFFAOYSA-N 0.000 claims 1
- HYYMQKPSPOQQOM-UHFFFAOYSA-N [4-(2-hydroxy-2-methylpropyl)piperidin-1-yl]-(5-nitro-1h-indol-2-yl)methanone Chemical compound C1CC(CC(C)(O)C)CCN1C(=O)C1=CC2=CC([N+]([O-])=O)=CC=C2N1 HYYMQKPSPOQQOM-UHFFFAOYSA-N 0.000 claims 1
- HADBDRAQLPRIJR-UHFFFAOYSA-N [4-(2-hydroxy-2-methylpropyl)piperidin-1-yl]-(6-methoxy-1h-indol-2-yl)methanone Chemical compound N1C2=CC(OC)=CC=C2C=C1C(=O)N1CCC(CC(C)(C)O)CC1 HADBDRAQLPRIJR-UHFFFAOYSA-N 0.000 claims 1
- KWOBLWBLBGAUPC-UHFFFAOYSA-N [4-(2-hydroxy-2-methylpropyl)piperidin-1-yl]-[5-(trifluoromethoxy)-1h-indol-2-yl]methanone Chemical compound C1CC(CC(C)(O)C)CCN1C(=O)C1=CC2=CC(OC(F)(F)F)=CC=C2N1 KWOBLWBLBGAUPC-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- -1 halo-C1-6alkyl Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Claims (11)
1. Spoj, naznačen time, da ima formulu (Ia) ili njegova sol:
[image]
gdje:
R1, R2 i R3, koji su međusobno isti ili različiti, predstavljaju H ili C1-6 alkil;
R4, R5, R6, R7 i R8, koji su međusobno isti ili različiti, predstavljaju sljedeće: H,
C1-6 alkil, halogen, halogen-C1-6alkil, nitro, -X-cikloalkil, koji može biti supstituiran, -X-aril, koji može biti supstituiran, -X-heterociklička skupina, koja može biti supstituirana, -X-COOR0, -X-CONR10R11, -X-CN, -X-OR0, -X-SR0, -X-S(O)-C1-6 alkil, -X-S (O)2-C1-6 alkil, -X-NR10R11, -X-NR0C(O)R10, -X-NR0C(O)OR10,
-X-NR0C(O)NR10R11, -X-NR0S(O)2R10, -X-O-halogen-C1-6 alkil, -X-O-X-cikloalkil, koji može biti supstituiran, -X-O-X-aril, koji može biti supstituiran, -X-O-X-heterociklička skupina, koja može biti supstituirana, ili -X-O-C1-6 alkilen-OR0; ili
R6 i R7 su kombinirani za tvorbu -O-C1-6 alkilen-O-;
R0, koji može biti isti ili različit, predstavlja H ili C1-6 alkil;
R10 i R11, koji su međusobno isti ili različiti, predstavljaju H, C1-6alkil,
halogen-C1-6alkil, -X-cikloalkil, -X-aril ili -X-heterocikličku skupinu; ili
R10 i R11, zajedno s N na koji su vezani, tvore zasićenu heterocikličku skupinu, koja može biti supstituirana; i
X, koji može biti isti ili različit, predstavlja vezu ili C1-6 alkilen.
2. Spoj prema zahtjevu 1 ili njegova sol, naznačen time, da R1 i R2 su C1-6 alkil, a R3 je H.
3. Spoj prema zahtjevu 2 ili njegova sol, naznačen time, da R4, R5, R7 i R8, koji su međusobno isti ili različiti, predstavljaju H, C1-6 alkil, halogen ili -O-C1-6 alkil.
4. Spoj prema zahtjevu 2 ili 3 ili njegova sol, naznačen time, da R6 je H, C1-6 alkil, halogen, halogen-C1-6 alkil, nitro, cikloalkil, OH ili -O-C1-6 alkil.
5. Spoj prema zahtjevu 4 ili njegova sol, naznačen time, da R6 je C1-6 alkil, halogen ili -O-C1-6 alkil.
6. Spoj prema zahtjevu 2, naznačen time, da je odabran iz skupine koju čine:
1-[1-(1H-indol-2-ilkarbonil)piperidin-4-il]-2-metilpropan-2-ol;
2-metil-1-{1-[(4-metil-1H-indol-2-il)karbonil]piperidin-4-il}propan-2-ol;
2-metil-1-{1-[(5-metil-1H-indol-2-il)karbonil]piperidin-4-il}propan-2-ol;
1-{1-[(3,5-dimetil-1H-indol-2-il)karbonil]piperidin-4-il}-2-metilpropan-2-ol;
1-{1-[(5-tert-butil-1H-indol-2-il)karbonil]piperidin-4-il}-2-metilpropan-2-ol;
1-{1-[(4-fluoro-1H-indol-2-il)karbonil]piperidin-4-il}-2-metilpropan-2-ol;
1-{1-[(5-fluoro-1H-indol-2-il)karbonil]piperidin-4-il}-2-metilpropan-2-ol;
1-{1-[(4-kloro-1H-indol-2-il)karbonil]piperidin-4-il}-2-metilpropan-2-ol;
1-{1-[(5-kloro-1H-indol-2-il)karbonil]piperidin-4-il}-2-metilpropan-2-ol;
1-{1-[(5-bromo-1H-indol-2-il)karbonil]piperidin-4-il}-2-metilpropan-2-ol;
1-{1-[(7-kloro-5-fluoro-1H-indol-2-il)karbonil]piperidin-4-il}-2-metilpropan-2-ol;
2-{[4-(2-hidroksi-2-metilpropil)piperidin-1-il]karbonil}-1H-indol-5-ol;
1-{1-[(4-metoksi-1H-indol-2-il)karbonil]piperidin-4-il}-2-metilpropan-2-ol;
1-{1-[(5-metoksi-1H-indol-2-il)karbonil]piperidin-4-il}-2-metilpropan-2-ol;
1-{1-[(6-metoksi-1H-indol-2-il)karbonil]piperidin-4-il}-2-metilpropan-2-ol;
2-metil-1-(1-{[5-(trifluorometoksi)-1H-indol-2-il]karbonil}piperidin-4-il)propan-2-ol; i
2-metil-1-{1-[(5-nitro-1H-indol-2-il)karbonil]piperidin-4-il}propan-2-ol,
ili njegova sol.
7. Farmaceutski sastav, naznačen time, da obuhvaća spoj prema zahtjevu 1 ili njegovu sol, te farmaceutski prihvatljivo pomoćno sredstvo.
8. Uporaba spoja prema zahtjevu 1 ili njegove soli, naznačena time, da je za proizvodnju farmaceutskog sastava za prevenciju ili liječenje bolesti povezane s 17βHSD tip 5.
9. Uporaba spoja prema zahtjevu 1 ili njegove soli, naznačena time, da je za proizvodnju farmaceutskog sastava za prevenciju ili liječenje raka prostate, benigne prostatske hiperplazije, akni, seboreje, hirzutizma, ćelavosti, alopecije, preuranjenog puberteta, adrenalne hipertrofije, sindroma policističnih jajnika, raka dojke, endometrioze, raka pluća ili lejomioma.
10. Komercijalni paket, naznačen time, da sadrži farmaceutski sastav, koji obuhvaća spoj prema zahtjevu 1 ili njegovu sol; te uputstvo da je spoj prema zahtjevu 1, ili njegova sol, pogodan za upotrebu ili bi ga trebalo upotrebljavati za liječenje i/ili prevenciju raka prostate, benigne prostatske hiperplazije, akni, seboreje, hirzutizma, ćelavosti, alopecije, preuranjenog puberteta, adrenalne hipertrofije, sindroma policističnih jajnika, raka dojke, endometrioze, raka pluća ili lejomioma.
11. Spoj prema zahtjevu 1 ili njegova sol, naznačen time, da je za uporabu u liječenju raka prostate, benigne prostatske hiperplazije, akni, seboreje, hirzutizma, ćelavosti, alopecije, preuranjenog puberteta, adrenalne hipertrofije, sindroma policističnih jajnika, raka dojke, endometrioze, raka pluća ili lejomioma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007225378 | 2007-08-31 | ||
| PCT/JP2008/065429 WO2009028618A1 (ja) | 2007-08-31 | 2008-08-28 | ピペリジン誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120837T1 true HRP20120837T1 (hr) | 2012-11-30 |
Family
ID=40387332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120837AT HRP20120837T1 (hr) | 2007-08-31 | 2012-10-18 | Derivati piperidina |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8513422B2 (hr) |
| EP (1) | EP2181990B1 (hr) |
| JP (1) | JP5327051B2 (hr) |
| KR (1) | KR20100050444A (hr) |
| CN (1) | CN101821253B (hr) |
| AU (1) | AU2008292420A1 (hr) |
| BR (1) | BRPI0815787A2 (hr) |
| CA (1) | CA2696799A1 (hr) |
| CY (1) | CY1113417T1 (hr) |
| DK (1) | DK2181990T3 (hr) |
| ES (1) | ES2392120T3 (hr) |
| HR (1) | HRP20120837T1 (hr) |
| MX (1) | MX2010002268A (hr) |
| PL (1) | PL2181990T3 (hr) |
| PT (1) | PT2181990E (hr) |
| RU (1) | RU2470020C2 (hr) |
| SI (1) | SI2181990T1 (hr) |
| TW (1) | TW200924765A (hr) |
| WO (1) | WO2009028618A1 (hr) |
| ZA (1) | ZA201000917B (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5609150B2 (ja) * | 2009-02-27 | 2014-10-22 | アステラス製薬株式会社 | ピペリジン誘導体 |
| JP2012102018A (ja) * | 2009-03-03 | 2012-05-31 | Astellas Pharma Inc | アミド化合物 |
| JP2012102017A (ja) * | 2009-03-03 | 2012-05-31 | Astellas Pharma Inc | インドール化合物 |
| JP5851998B2 (ja) * | 2009-10-27 | 2016-02-03 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 殺虫剤および殺ダニ剤としてのハロアルキル置換アミド |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9116732D0 (en) | 1991-08-02 | 1991-09-18 | Fujisawa Pharmaceutical Co | Indole derivatives |
| AU680870B2 (en) | 1993-04-28 | 1997-08-14 | Astellas Pharma Inc. | New heterocyclic compounds |
| JP2002515891A (ja) | 1997-12-19 | 2002-05-28 | スミスクライン・ビーチャム・コーポレイション | 新規なピペリジン含有化合物 |
| CA2323089A1 (en) | 1998-03-11 | 1999-09-16 | Endorecherche, Inc. | Inhibitors of type 5 and type 3 17.beta.-hydroxysteroid dehydrogenase and methods for their use |
| ID28791A (id) * | 1998-08-07 | 2001-07-05 | Endorech Inc | PENGHAMBATAN DEHIDROGENASE HIDROKSISTEROID 3α TIPE 3 |
| AU2002211901A1 (en) * | 2000-10-10 | 2002-04-22 | Smithkline Beecham Corporation | Substituted indoles, pharmaceutical compositions containing such indoles and their use as PPAR-gamma binding agents |
| US6803362B2 (en) | 2001-03-09 | 2004-10-12 | Ortho-Mcneil Pharmaceutical Inc. | Heterocyclic compounds |
| JP4623962B2 (ja) | 2001-10-22 | 2011-02-02 | ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク | タンパク質キナーゼおよびホスファターゼ阻害剤、それらを設計する方法、ならびにそれらを使用する方法 |
| WO2003049736A1 (en) | 2001-12-11 | 2003-06-19 | Sepracor, Inc. | 4-substituted piperidines, and methods of use thereof |
| ES2254046T1 (es) | 2003-01-17 | 2006-06-16 | Threshold Pharmaceuticals, Inc. | Tratamiento de hiperplasia prostatica benigna. |
| WO2004089470A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | New amide derivatives and pharmaceutical use thereof |
| MXPA06002018A (es) | 2003-08-21 | 2006-05-31 | Osi Pharm Inc | Bencimidazolilo n-sustituidos inhibidores de c-kit. |
| WO2005040112A1 (en) * | 2003-10-14 | 2005-05-06 | Oxagen Limited | Compounds with pgd2 antagonist activity |
| JP2005162657A (ja) | 2003-12-02 | 2005-06-23 | Takeda Chem Ind Ltd | カンナビノイド受容体調節剤 |
| JPWO2005082905A1 (ja) * | 2004-02-26 | 2007-08-02 | 協和醗酵工業株式会社 | 二環性複素環化合物 |
| EP1771413B1 (en) * | 2004-05-03 | 2011-09-21 | Janssen Pharmaceutica NV | Benzofuran derivatives as selective androgen receptor modulators (sarms) |
| AU2005243238B2 (en) * | 2004-05-03 | 2011-11-10 | Janssen Pharmaceutica N.V. | Novel indole derivatives as selective androgen receptor modulators (SARMS) |
| MXPA06014810A (es) * | 2004-06-21 | 2007-02-12 | Hoffmann La Roche | Derivados de indol como antagonistas receptores de histamina. |
| JP2009509932A (ja) | 2005-09-07 | 2009-03-12 | プレキシコン，インコーポレーテッド | Ｐｐａｒ活性化合物 |
| EP2298770A1 (en) | 2005-11-03 | 2011-03-23 | ChemBridge Corporation | Heterocyclic compounds as TrkA modulators |
| WO2007100066A1 (ja) * | 2006-03-02 | 2007-09-07 | Astellas Pharma Inc. | １７βＨＳＤｔｙｐｅ５阻害剤 |
-
2008
- 2008-08-28 PT PT08828181T patent/PT2181990E/pt unknown
- 2008-08-28 RU RU2010112412/04A patent/RU2470020C2/ru not_active IP Right Cessation
- 2008-08-28 SI SI200830756T patent/SI2181990T1/sl unknown
- 2008-08-28 PL PL08828181T patent/PL2181990T3/pl unknown
- 2008-08-28 BR BRPI0815787-1A2A patent/BRPI0815787A2/pt not_active IP Right Cessation
- 2008-08-28 AU AU2008292420A patent/AU2008292420A1/en not_active Abandoned
- 2008-08-28 JP JP2009530181A patent/JP5327051B2/ja not_active Expired - Fee Related
- 2008-08-28 MX MX2010002268A patent/MX2010002268A/es active IP Right Grant
- 2008-08-28 ES ES08828181T patent/ES2392120T3/es active Active
- 2008-08-28 EP EP08828181A patent/EP2181990B1/en active Active
- 2008-08-28 CA CA2696799A patent/CA2696799A1/en not_active Abandoned
- 2008-08-28 KR KR1020097027327A patent/KR20100050444A/ko active IP Right Grant
- 2008-08-28 CN CN2008801044156A patent/CN101821253B/zh not_active Expired - Fee Related
- 2008-08-28 TW TW097132959A patent/TW200924765A/zh unknown
- 2008-08-28 US US12/675,744 patent/US8513422B2/en active Active
- 2008-08-28 DK DK08828181.1T patent/DK2181990T3/da active
- 2008-08-28 WO PCT/JP2008/065429 patent/WO2009028618A1/ja active Application Filing
-
2010
- 2010-02-08 ZA ZA2010/00917A patent/ZA201000917B/en unknown
-
2012
- 2012-10-16 CY CY20121100957T patent/CY1113417T1/el unknown
- 2012-10-18 HR HRP20120837AT patent/HRP20120837T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0815787A2 (pt) | 2015-02-24 |
| EP2181990A1 (en) | 2010-05-05 |
| EP2181990A4 (en) | 2011-09-07 |
| PL2181990T3 (pl) | 2013-01-31 |
| JP5327051B2 (ja) | 2013-10-30 |
| AU2008292420A1 (en) | 2009-03-05 |
| RU2010112412A (ru) | 2011-10-10 |
| JPWO2009028618A1 (ja) | 2010-12-02 |
| CY1113417T1 (el) | 2016-06-22 |
| EP2181990B1 (en) | 2012-08-08 |
| US8513422B2 (en) | 2013-08-20 |
| TW200924765A (en) | 2009-06-16 |
| CN101821253A (zh) | 2010-09-01 |
| WO2009028618A1 (ja) | 2009-03-05 |
| RU2470020C2 (ru) | 2012-12-20 |
| CA2696799A1 (en) | 2009-03-05 |
| PT2181990E (pt) | 2012-10-16 |
| KR20100050444A (ko) | 2010-05-13 |
| CN101821253B (zh) | 2013-07-17 |
| US20100256189A1 (en) | 2010-10-07 |
| ZA201000917B (en) | 2011-04-28 |
| ES2392120T3 (es) | 2012-12-04 |
| DK2181990T3 (da) | 2012-09-10 |
| MX2010002268A (es) | 2010-03-25 |
| SI2181990T1 (sl) | 2012-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120837T1 (hr) | Derivati piperidina | |
| ES2337254T3 (es) | Derivados de carboxamida. | |
| NZ594597A (en) | Substituted piperidines as ccr3 antagonists | |
| PE20091974A1 (es) | Derivados de indazoles sustituidos con fenil o piridinilo | |
| ES2261476T3 (es) | Derivados de quinolina y quinazolina que inhiben la farnesil-tranferasa como inhibidores de farnesil-tranferasa. | |
| PE20060598A1 (es) | Derivado heterociclo conteniendo nitrogeno como antagonista de quimiocina ccr5 | |
| AR054889A1 (es) | Derivados de quinolina como agentes bacterianos | |
| PE20060011A1 (es) | COMPUESTOS AMIDAS DE ACIDOS CARBOXILICOS COMO INHIBIDORES DEL FACTOR Xa | |
| JP2011510929A5 (hr) | ||
| AR034405A1 (es) | Composiciones farmaceuticas que contienen derivados de 3-amino-azetidina, los nuevos derivados y su preparacion | |
| PE20060298A1 (es) | Derivados de acido carboxilico de bencimidazolona | |
| HRP20110640T1 (hr) | Derivati cikličkih amida i njihova proizvodnja te njihova uporaba kao antitromboznih sredstava | |
| UA99361C2 (uk) | ТРИАЗИНИ ЯК ІНГІБІТОРИ PІ3-КІНАЗИ І mTOR | |
| NZ600400A (en) | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | |
| JP2002533454A (ja) | 芳香族アミド類 | |
| MX2012002011A (es) | Composicion farmaceutica que contiene derivado de quinolina. | |
| PT2066659E (pt) | Derivados de sulfonamida substituídos | |
| AR031809A1 (es) | Quinolonas antimicrobianas, sus composiciones y usos | |
| WO2010080357A1 (en) | Serotonin 5-ht2b receptor inhibitors | |
| AR076562A1 (es) | Derivados de ciclopenta (c) pirrol-2- carboxilatos, su preparacion y su aplicacion en terapeutica | |
| ES2537801T3 (es) | Piperazinodionas como antagonistas del receptor de la oxitocina | |
| TW200726764A (en) | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | |
| UA90742C2 (en) | Pyrazolone derivatives | |
| WO2006125181A3 (en) | Piperidine derivatives and their use as stearoyl-coa desaturase modulators | |
| AR073380A1 (es) | Composicion farmaceutica solida. comprimido multicapa |